Ya-Wen Chuang1, Mei-Ching Yu, Shih-Ting Huang, Cheng-Kuang Yang, Cheng-Hsu Chen, Ying-Chih Lo, Cheng-Li Lin, Kuo-Hsiung Shu, Tung-Min Yu, Chia-Hung Kao. 1. aDivision of Nephrology, Taichung Veterans General Hospital, TaichungbDepartment of Pediatric Nephrology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, TaoyuancDivision of Urology, Taichung Veterans General HospitaldManagement Office for Health Data, China Medical University HospitaleCollege of Medicine, China Medical UniversityfGraduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical UniversitygDepartment of Nuclear Medicine and PET Center, China Medical University HospitalhDepartment of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan.
Abstract
AIM: This was a nationwide study by National Health Insurance Research Database to investigate the risk of urinary tract cancers (UTCs) for renin-angiotensin-aldosterone system inhibitors including spironolactone. METHODS: A total of 32 167 UTC patients with hypertension were enrolled in the National Health Insurance program between 2005 and 2011. RESULTS: Among different subclasses of renin-angiotensin-aldosterone system inhibitors, the adjusted odds ratio (OR) for UTC risk was 1.00 [95% confidence interval (CI) = 0.96-1.04] in angiotensin-converting enzyme inhibitors, 1.22 (95% CI = 1.18-1.26) in patients who received angiotensin II receptor blockers, 0.91 (95% CI = 0.87-0.96) in spironolactone. Spironolactone is associated with a significantly lower risk of prostate cancer (adjusted OR = 0.88, 95% CI = 0.82-0.94) in the male patients. A similar trend was observed in the female patients for the risk of bladder cancer (adjusted OR = 0.81, 95% CI = 0.72-0.92). CONCLUSION: Our findings show that a lower risk of UTCs significantly associated with spironolactone in patients.
AIM: This was a nationwide study by National Health Insurance Research Database to investigate the risk of urinary tract cancers (UTCs) for renin-angiotensin-aldosterone system inhibitors including spironolactone. METHODS: A total of 32 167 UTC patients with hypertension were enrolled in the National Health Insurance program between 2005 and 2011. RESULTS: Among different subclasses of renin-angiotensin-aldosterone system inhibitors, the adjusted odds ratio (OR) for UTC risk was 1.00 [95% confidence interval (CI) = 0.96-1.04] in angiotensin-converting enzyme inhibitors, 1.22 (95% CI = 1.18-1.26) in patients who received angiotensin II receptor blockers, 0.91 (95% CI = 0.87-0.96) in spironolactone. Spironolactone is associated with a significantly lower risk of prostate cancer (adjusted OR = 0.88, 95% CI = 0.82-0.94) in the male patients. A similar trend was observed in the female patients for the risk of bladder cancer (adjusted OR = 0.81, 95% CI = 0.72-0.92). CONCLUSION: Our findings show that a lower risk of UTCs significantly associated with spironolactone in patients.
Authors: Bryan Williams; Thomas M MacDonald; Steve V Morant; David J Webb; Peter Sever; Gordon T McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Sandosh Padmanabhan; Isla S Mackenzie; Jackie Salsbury; Morris J Brown Journal: Lancet Diabetes Endocrinol Date: 2018-04-11 Impact factor: 32.069
Authors: Lisa Haimerl; Dorothea Strobach; Hanna Mannell; Christian G Stief; Alexander Buchner; Alexander Karl; Tobias Grimm Journal: Int J Clin Pharm Date: 2021-11-01